A new risk factor for coronary artery disease can be detected by an ApoA1 mAb-based assay

Hui Ding,Yin Wang,Yan Zhang,Lida Zhou,Dong Wang,Liangjie Lv,Qianli Wan,Minghong Tong,Chenxia Deng,Huihong Xu,Bailing Zu,Jie Zhang,Zhaohui Qiu,Huiming Sheng
DOI: https://doi.org/10.1016/j.cca.2023.117700
IF: 6.314
2023-12-12
Clinica Chimica Acta
Abstract:Background This study aimed to find coronary artery disease (CAD) related apolipoprotein A1 (ApoA1) monoclonal antibody (mAb) and to evaluate the diagnostic value of the assay based on it. Methods Patients with CAD diagnosed by coronary angiography (disease group, n = 180) and healthy subjects (control group, n = 199) were recruited. The correlation between methods and CAD were evaluated by Spearman's rank correlation coefficients. Receiver operating characteristic (ROC) curve analysis was used to evaluate the auxiliary diagnostic value of methods for CAD. Odds ratios (ORs) of the test results in CAD were estimated using logistic regression analysis. Results Measurements from an ApoA1 mAb were found significantly positively correlated with CAD (r = 0.243, P < 0.01), unlike the measurements from the ApoA1 pAb were negatively correlated with CAD (r = -0.341, P < 0.001). The areas under the ROC curve of the ApoA1 mAb and pAb measurements were 0.704 and 0.563, respectively, in patients with normal HDL-C levels. ApoA1 values from the mAb assay had a significant positive impact on CAD risk. Conclusion An ApoA1 mAb-based assay can distinguish a high-density lipoprotein (HDL) subclass positively related to CAD, which can be used to improve and reappraise CAD risk assessment.
medical laboratory technology
What problem does this paper attempt to address?